• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

The Inflation Reduction Act: Implications for Patient Access in CL

Opinion
Video

A group of experts discuss implications for patient access in CLL.

Video content above is prompted by the following question(s):

  1. What efforts are being made to improve affordability and access to BTK inhibitors for all patients who could benefit from them?

 

  1. Ibrutinib was selected for the first round of Medicare drug price negotiations, a key component of the Inflation Reduction Act (IRA). How might this negotiation impact patient access to BTK inhibitor therapy?
Related Videos
Pierluigi Porcu, MD
Related Content
While pausing therapy did not affect response to vaccination, the investigators noted that participants who paused therapy did have higher rates of self-reported lymphadenopathy. | Image credit: Konstantin Yuganov - stock.adobe.com

Pausing BTK Inhibitors Does Not Strengthen COVID Vaccination in CLL

April 18th 2025
Article

Previous work had suggested pausing Bruton tyrosine kinase (BTK) inhibitors before COVID-19 vaccination might boost immunity in patients with chronic lymphocytic leukemia (CLL).

Read More

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

December 17th 2024
Podcast

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.

Listen

The researchers examined outcomes in a series of patients with RT who were treated with liso-cel, including patients who were also taking ibrutinib. | Image credit: AIGen - stock.adobe.com

Ibrutinib May Boost Efficacy of Liso-Cel in CLL With Richter Transformation

April 10th 2025
Article

Patients with chronic lymphocytic leukemia (CLL) who experience Richter transformation have a poor prognosis, but ibrutinib may help boost the efficacy of chimeric antigen receptor T-cell therapies.

Read More

Recent trials have explored potential strategies for using immunotherapy in chronic lymphocytic leukemia. | Image credit: Spectral-Design - stock.adobe.com

Immune Microenvironment a Key Target in CLL

April 8th 2025
Article

A number of recent trials have explored potential strategies for using immunotherapy in chronic lymphocytic leukemia (CLL).

Read More

Patient visit with pharmacist | Image credit : Chinnapong – stock.adobe.com

Pharmacist-Led Model Reduces Tumor Lysis Risk in CLL Venetoclax Therapy

April 3rd 2025
Article

New findings may help patients with low to moderate risk of tumor lysis syndrome while reducing the burden for hematologists.

Read More

Woman taking pills from bottle | Image credit: Rawpixel.com – stock.adobe.com

In CLL, Zanubrutinib Shows Better Safety Profile Than Ibrutinib

March 20th 2025
Article

A study of 200 patients with chronic lymphocytic leukemia (CLL) showed a lower rate of severe and serious adverse events among those treated with zanubrutinib compared with ibrutinib.

Read More

© 2025 MJH Life Sciences
AJMC®
All rights reserved.